Replimune Group, Inc. issued a news release on June 29, 2026, announcing its financial results for the fourth fiscal quarter and the full fiscal year ended March 31, 2026. The company provides corporate updates alongside its financial performance. Replimune Group, Inc. is a biotechnology company focused on developing oncolytic virotherapy products.
